Gaboxadol
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
64603-91-4  |
| PubChem (CID) | 3448 |
| IUPHAR/BPS | 4322 |
| ChemSpider |
3330  |
| UNII |
K1M5RVL18S |
| KEGG |
D04282 |
| ChEMBL |
CHEMBL312443 |
| ECHA InfoCard | 100.059.039 |
| Chemical and physical data | |
| Formula | C6H8N2O2 |
| Molar mass | 140.14 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), is a conformationally constrained derivative of the alkaloid muscimol that was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-Larsen.[1] In the early 1980s gaboxadol was the subject of a series of pilot studies that tested its efficacy as an analgesic and anxiolytic, as well as a treatment for tardive dyskinesia, Huntington's disease, Alzheimer's disease, and spasticity.[1] It was not until 1996 that researchers attempted to harness gaboxadol's frequently reported sedative "adverse effect" for the treatment of insomnia, resulting in a series of clinical trials sponsored by Lundbeck and Merck.[1][2] In March, 2007, Merck and Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a different way from benzodiazepines, Z-Drugs, and barbiturates. Lundbeck states that gaboxadol also increases deep sleep (stage 4). It is, however, not reinforcing like benzodiazepines are.[3]
In 2015, Lundbeck sold its rights to the molecule to Ovid Therapeutics, whose plan is to develop it for FXS and Angelman Syndrome.[4]
See also
References
- 1 2 3 Morris, Hamilton (August 2013). "Gaboxadol". Harper's Magazine. Retrieved 2014-11-20.
- ↑ US Patent 4278676 - Heterocyclic compounds
- ↑ Vashchinkina, E; Panhelainen, A; Vekovischeva, O. Y.; Aitta-Aho, T; Ebert, B; Ator, N. A.; Korpi, E. R. (2012). "GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons". Journal of Neuroscience. 32 (15): 5310–20. doi:10.1523/JNEUROSCI.4697-11.2012. PMID 22496576.
- ↑ Tirrell, Meg (16 April 2015). "Former Teva CEO's new gig at Ovid Therapeutics". CNBC. Retrieved 2015-05-06.
External links
- 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol at the US National Library of Medicine Medical Subject Headings (MeSH)
- H. Lundbeck Website
- Medical News Today article
- Report of cancellation of development.
- Gaboxadol